参考文献/References:
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018: GLOBOCAN estimatesof incidence and mortality worldwide for 36 cancers in185 countries[J]. CA Cancer J. Clin,2018,68(6):394-424.
[2] 周晓艳, 李越, 何谦, 等.Prohibitin 表达及对乳腺癌细胞系MCF-7 抑制生长的机制研究[J]. 现代检验医学杂志,2020,35(3):6-10, 19.ZHOU Xiaoyan, LI Yue, HE Qian, et al. Expression ofprohibitin and its retrain mechanism to growth in thebreast cancer cell MCF-7 [J]. Journal of Modern LaboratoryMedicine,2020,35(3):6-10, 19.
[3] 赵晶, 吴楠, 张世超, 等. 乳腺癌靶向治疗新进展[J].中华肿瘤杂志,2020,42(5):353-361.ZHAO Jing, WU Nan, ZHANG Shichao, et al. Newadvances in targeted therapy for breast cancer [J].Chinese Journal of Oncology,2020,42(5):353-361.
[4] 张鑫浩, 张涛元, 李俏, 等. 基于GEO 芯片数据的肝癌关键生物标志物的筛选与鉴定及生物信息学分析[J]. 现代检验医学杂志,2020,35(4):26-31.ZHANG Xinhao, ZHANG Taoyuan, LI Qiao, et al.Screening, identification and bioinformatics analysisof key biomarkers for Hepatocellular carcinoma basedon GEO chip data [J]. Journal of Modern LaboratoryMedicine,2020,35(4):26-31.
[5] 张百红, 岳红云. 肿瘤新特征研究进展[J]. 现代肿瘤医学,2021,29(11):2009-2013.ZHANG Baihong, YUE Hongyun. Hallmarks ofcancer: The new decade[J].Modern Oncology,2011,29(11):2009-2013.
[6] TAPIA J C, NIECHI I. Endothelin-convertingenzyme-1 in cancer aggressiveness[J]. Cancer Letters,2019, 452:152-157.
[7] HEYMAN S N,ABASSI Z,ROSENBERGER C,etal. Cyclosporine A induces endothelin-convertingenzyme (ECE)-1: studies in-vivo and in-vitro[J]. ActaPhysiologica, 2018, 223(1):e13033.
[8] 郭安源. 基因转录表达数据的生物信息挖掘研究[J].中国科学：生命科学,2021,51(1):70-82.GUO Anyuan .Bioinformatics mining for geneexpression data [J]. Science in China: Life Sciences,2021,51(1):70-82.
[9] WU P,HEINS Z J,MULLER J T,et al. Integration andanalysis of CPTAC proteomics data in the contextof cancer genomics in the cBioPortal[J]. Mol CellProteomics, 2019, 18(9):1893-1898.
[10] BUCHSBAUM I Y , KIELKOWSKI P , GIORGIOG, et al. ECE2 regulates neurogenesis and neuronalmigration during human cortical development[J].EMBO Reports, 2020, 21(5):e48204.
[11] LIAO Xinxin, CAI Fang, SUN Zhanfang, et al.Identification of Alzheimer’s disease-associatedrare coding variants in the ECE2 gene[J]. JCIInsight,2020,5(4):e135119.
[12] SHEN Yong,NAR R,FAN A X,et al. Functionalinterrelationship between TFII-I and E2F transcriptionfactors at specific cell cycle gene loci[J]. J CellBiochem, 2018,119(1):712-722.
[13] LU Guanming, LI Yueyong, MA Yanfei,et al. Longnoncoding RNA LINC00511 contributes to breastcancer tumour genesis and stemness by inducing themiR-185-3p/E2F1/Nanog axis[J]. J Exp Clin CancerRes,2018,37(1):289.
[14] LIU Bowen, WANG Tianjiao, LI Leilei,et al. OncoproteinHBXIP induces PKM2 via transcription factorE2F1 to promote cell proliferation in ER-positive breastcancer[J]. Acta Pharmacol Sin,2019,40(4):530-538.
[15] 沈诚, 李珏, 常帅, 等.E2F1 在常见肿瘤中的最新研究进展[J]. 中国肺癌杂志,2020,23(10):921-926.SHEN Cheng, LI Jue, CHANG Shuai, et al.Advancement of E2F1 in common tumors[J]. ChineseJournal of Lung Cancer,2020,23(10):921-926.
[16] SUTTON M N, HUANG G Y, ZHOU Jinhua, et al.Abstract 1325: DIRAS3 (ARHI) is required for aminoacid-mediated autophagy and nutrient deprivation indormant ovarian cancers[J]. Cancer Research,2018,78(13 suppl):1325.
[17] WANG Chen, ZHANG Jiawei, YIN Jie , et al.Alternative approaches to target Myc for cancertreatment[J]. Signal Transduction and Targeted Therapy,2021, 6(1):117.
[18] CINZIA C, MARCO P, VALENTINA P, et al. c-MYCempowers transcription and productive splicing of theoncogenic splicing factor Sam68 in cancer[J]. NuclcAcids Research, 2019,47(12):6160-9171.
[19] ZHOU Yu, GENG Yan, ZHANG Yujiao, et al. Therequirement for cyclin E in c-Myc overexpressingbreast cancers[J]. Cell Cycle, 2020,19(20):2589-2599.
[20] LI H S, L? R Q, LIU L. Correlation of CT indicatorsof NSCLC and pathological features and the expressionlevel of p53 and c-myc [J]. Eur Rev Med PharmacolSci,2018, 22(1):135-141.
[21] SHENG Xia , NENSETH H Z , QU Su, et al. IRE1α-XBP1s pathway promotes prostate cancer by activatingc-MYC signaling[J]. Nature Communications, 2019,10(1):323.
相似文献/References:
[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis
Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2
和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2
and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(04):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T
Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and
Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level
in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(04):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell
s[J].Journal of Modern Laboratory Medicine,2017,32(04):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A
>T(rs290987)Single Nucleotide Polymorphisms with Susceptibility
to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(04):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating
Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(04):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]